Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Initiated - COVID-19 Clinical Trial
Breaking News | COVID-19

Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Initiated

APEIRON Biologics AG today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19. The randomized, double-blind Phase II trial will compare APN01 to placebo in up to 200 patients at 10 sites in Austria, Denmark and Germany. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), and has the potential to block the infection of cells by the novel SARS-CoV-2 virus (COVID-19), and reduce lung injury.  


UNM Hospital to Launch Clinical Trials for COVID-19 

This week, doctors at the University of New Mexico Hospital launched their first two clinical trials of two different medicines to help treat patients fighting the coronavirus. Hydroxychloroquine will help patients who are hospitalized who are experiencing respiratory distress and Remdesivir will be given to people who have pneumonia symptoms. 


Abbott Receives Approval for Test That Can Detect Coronavirus in 5 Minutes

Abbott on Friday announced it received approval for a test that is capable of delivering positive results of the coronavirus in as little as five minutes, and it will begin making those tests available to health care providers next week. This is the second Abbott test for the coronavirus to be launched. Between the two, the company expects to produce about 5 million tests per month, the company said in a statement. 

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.